Primary lateral sclerosis (PLS) is a motor neuron disease that occurs when the nerve cells in muscles slowly deteriorate. This leads to weakness in the voluntary muscles like the tongue ...

The Global Amyotrophic Lateral Sclerosis Treatment Market was valued at USD 634 Million in 2023 and expected to grow USD 1021 Million in 2032.

MNDs are neurological disorders that destroy motor neurons, the cells that control skeletal muscle activity such as walking, breathing, speaking, and swallowing.

Motor neuron disease usually refers to amyotrophic lateral sclerosis, but it can also refer to other kind of neurodegenerative disease that affect the motor neurons, such as progressive primary ...

The Massachusetts based biotech will now press ahead with human trials for its antisense oligonucleotide (ASO) therapy, ...

A 3D model accurately mimicking the Blood-Brain Barrier (BBB) in a laboratory environment has been successfully developed by ...

Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...

Compared to placebo, the study did not meet the primary endpoint of efficacy in slowing disease progression. The primary endpoint was evaluated as a change in disease severity over time as ...

Ncardia, a global leader in human induced pluripotent stem cell (hiPSC) technology, today announced the launch of Ncyte® ...

Methods Cohort recruited via a specialist, multidisciplinary clinic. Patients were categorised into four clinical phenotypes (ALS, flail arm, flail leg and primary lateral sclerosis) according to site ...

DNL343 For The Treatment Of Patients With Amyotrophic Lateral Sclerosis As I stated directly above, Denali Therapeutics reported that it had failed to meet the primary endpoint of the phase 2/3 ...